Table 1.
Baseline Demographic of the Ineffective and Effective Groups Treated with Rituximab for Refractory Membranous Nephropathy
| Indices | Ineffective Group (n=47) | Effective Group (n=113) | P |
|---|---|---|---|
| Sex [n (%)] | 0.527 | ||
| Male | 39 (82.98) | 88 (77.88) | |
| Female | 8 (17.02) | 25 (22.12) | |
| Age (years) | 34.83±4.61 | 35.96±4.75 | 0.167 |
| BMI (kg/m2) | 23.54±1.83 | 24.00±1.88 | 0.152 |
| Course (years) | 31.96±4.68 | 30.44±5.34 | 0.093 |
| ALB (g/L) | 22.26±3.40 | 26.74±3.43 | <0.001 |
| SCr (umol/L) | 94.96±12.40 | 81.11±9.33 | <0.001 |
| 24h urine protein (g/d) | 8.24±1.97 | 6.08±1.96 | <0.001 |
| eGFR [mL·min-1· (1.73 m2)-1] | 76.83±10.23 | 89.10±10.18 | <0.001 |
| T-CHO (mmol/L) | 6.70±0.47 | 6.54±0.53 | 0.084 |
| TG (mmol/L) | 2.27±0.37 | 2.39±0.44 | 0.094 |
| PLA2R-Ab (RU/mL) | 49.86±8.98 | 41.41±8.65 | <0.001 |
Abbreviations: BMI, body mass index; ALB, serum albumin; SCr, serum creatinine; 24h-UP, 24-hour urine protein; eGFR, estimated glomerular filtration rate; T-CHO, total cholesterol; TG, triglycerides; PLA2R-Ab, phospholipase A2 receptor antibody;